Entero Healthcare Solutions Limited
₹1,573.85+₹14.55 (+0.9%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹5,316 Cr
- P/E
- 124.0x
- EV / EBITDA
- 89.2x
- Revenue
- ₹409 Cr
- Net margin
- 11.9%
- ROCE
- -2.1%
Price chart
Technical chartScreen technicals →+42.3% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- -8.0%
- 3M
- +26.1%
- 6M
- +28.9%
- 1Y
- +42.3%
- 5Y
- +36.9%
52-week range
Day change +₹14.55 (+0.9%) from ₹1,559 to ₹1,574 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in ENTERO, bought on each weekday since 2024.
AI Summary
Indian StockStrengths1
- Strong 5-year revenue CAGR of 41.5%
Concerns1
- Low return on equity of 2.3%
Rule-based from financial data. Not advice.
About the company
Entero Healthcare Solutions Limited engages in the distribution and marketing of pharmaceutical, surgical products and other allied services in India. The company involved in the distribution of generic formulations, active pharmaceutical ingredients, surgical consumables, rehabilitation products and devices, over the counter medical products, nutraceuticals, biosimilars, and biologics.
Read moreShow less
Entero Healthcare Solutions Limited engages in the distribution and marketing of pharmaceutical, surgical products and other allied services in India. The company involved in the distribution of generic formulations, active pharmaceutical ingredients, surgical consumables, rehabilitation products and devices, over the counter medical products, nutraceuticals, biosimilars, and biologics. It also provides nebulizers, personal protective, hygiene and surgical consumable products, homecare medical devices, gloves and mobility equipment, digital thermometers. In addition, the company offers healthcare products, including pharmaceutical and nutraceutical products, vaccines, medical devices, such as orthopaedic implants and coronary stents, and hospital consumables comprising examination and surgical gloves, syringes, needles and sutures to hospitals, retail pharmacies, healthcare product manufacturers, and healthcare clinics. Entero Healthcare Solutions Limited was incorporated in 2018 and is based in Mumbai, India.
- Sector
- Healthcare
- Shares outstanding
- 4.3 Cr shares
- ISIN
- INE010601016
- BSE code
- 544122
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹5,316 Cr
- P/E
- 124.0x
- P/B
- 3.2x
- EV / EBITDA
- 89.2x
- EV / Sales
- 15.7x
- P/S
- 16.7x
- Earnings yield
- 0.8%
- 52-week high
- ₹1,891.50
- 52-week low
- ₹949.80
Profitability
- Operating margin
- -10.7%
- Net margin
- 11.9%
- EBITDA margin
- 17.6%
- ROE
- 2.3%
- ROCE
- -2.1%
- ROA
- 2.1%
- Dividend payout
- 0.0%
- Tax rate
- -58.0%
- Other income, % of PBT
- 375.0%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹409 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 28.6%
- Revenue CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 41.5%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹56.0 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 522.2%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -50.0%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -₹76.0 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 33.3%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹58.0 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 131.5%
Solvency and efficiency
- Current ratio
- 13.88
- Debt / Equity
- 0.01
- Debt / Assets
- 0.01
- Debt / EBITDA
- 0.32
- Financial leverage
- 1.09
- CFO / Net profit
- -2.00
- Cash / Market cap
- 31.9%
- Cash per share
- ₹390.04
- Asset turnover
- 0.18
- Fixed asset turnover
- 9.35
- Capital intensity
- 0.11
- Debtor days
- 130 days
- Inventory turnover
- 5.62
- Cash conversion cycle
- 107 days
Where the revenue went
FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.
| Line | FY2025 |
|---|---|
| Sales | ₹409 Cr |
| Expenses | ₹439 Cr |
| Operating profit | -₹30 Cr |
| Other income | ₹67 Cr |
| Interest | ₹2 Cr |
| Depreciation | ₹9 Cr |
| Profit before tax | ₹27 Cr |
| Tax and other | ₹8 Cr |
| Net profit | ₹19 Cr |
Revenue and net profit
Revenue grew 28.6% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹105 Cr | -₹18 Cr |
| FY2022 | ₹137 Cr | -₹41 Cr |
| FY2023 | ₹178 Cr | -₹12 Cr |
| FY2024 | ₹318 Cr | ₹38 Cr |
| FY2025 | ₹409 Cr | ₹19 Cr |
Cash flows
FY2025: -₹109 Cr from operations, ₹99.0 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | -₹68 Cr | -₹75 Cr |
| FY2022 | -₹45 Cr | -₹114 Cr |
| FY2023 | -₹57 Cr | -₹115 Cr |
| FY2024 | -₹76 Cr | -₹839 Cr |
| FY2025 | -₹109 Cr | ₹99 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹409 Cr+28.6%1Y
- Net profit
- ₹19 Cr-50.0%1Y
- Cash from operations
- -₹109 Cr
- Free cash flow
- ₹99 Cr
- Revenue CAGR, 5Y
- 41.5%
- EBITDA CAGR, 5Y
- 69.5%
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹409 Cr | -₹30 Cr | — | ₹19 Cr | -₹109 Cr | ₹99 Cr | 1.2% | +28.6% | -50.0% |
Monthly returns
Month-by-month returns of ENTERO across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹1,804 Cr |
| Equity capital | ₹44 Cr |
| Reserves | ₹1,607 Cr |
| Borrowings | ₹14 Cr |
| Other liabilities | ₹139 Cr |
| Assets | ₹1,804 Cr |
| Fixed assets | ₹28 Cr |
| Capital work in progress | ₹0 Cr |
| Investments | ₹277 Cr |
| Other assets | ₹1,498 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
ENTERO trades at 124.0x earnings against a peer median of 52.6x (a 136% premium).
Not shown (no positive earnings and no EV / Sales): Sun Pharma Advanced Research Company Ltd.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Entero Healthcare Solutions LimitedENTEROthis companyP/E ↑ premium | ₹5,316 Cr | 124.0x | 3.2x | 2.3% | 89.2x |
| PARK MEDI WORLD LIMITEDPARKHOSPS | ₹6,504 Cr | 906.0x | — | 7.0% | 214.8x |
| FDC Ltd.FDC | ₹6,387 Cr | 27.0x | 2.6x | 14.6% | 14.2x |
| YATHARTH HOSPITAL & TRAUMA CARE SERVICES LIMITEDYATHARTH | ₹6,186 Cr | 67.3x | 3.9x | 10.0% | 45.5x |
| Kovai Medical Center & Hospital LtdKOVAI | ₹6,071 Cr | 26.6x | 5.1x | 20.2% | 17.2x |
| Supriya Lifescience LimitedSUPRIYA | ₹5,938 Cr | 32.6x | 5.5x | 14.6% | 31.4x |
| Shilpa Medicare Ltd.SHILPAMED | ₹5,771 Cr | 52.6x | 2.2x | 1.3% | 53.7x |
| Nephrocare Health Services LimitedNEPHROPLUS | ₹4,815 Cr | 141.0x | — | 1.0% | 82.3x |
| Sun Pharma Advanced Research Company Ltd.SPARC | ₹4,415 Cr | — | -12.6x | -312.9% | -11.7x |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
ENTERO since 1 January, against earlier years.
Historical volatility
ENTERO's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | -30.0% |
| FY2022 | -39.0% |
| FY2023 | -25.0% |
| FY2024 | -11.0% |
| FY2025 | -7.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹409 Cr |
| Costs | |
| Interest | ₹2 Cr |
| Expenses | ₹439 Cr |
| Operating profitOperating Profit | -₹30 Cr |
| Other income and charges | |
| Profit before tax | ₹27 Cr |
| Tax | |
| Net profitNet Profit | ₹19 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹1,804 Cr |
| Equity capitalEquity Capital | ₹44 Cr |
| Reserves | ₹1,607 Cr |
| Borrowings | ₹14 Cr |
| Other liabilitiesOther Liabilities | ₹139 Cr |
| AssetsTotal Assets | ₹1,804 Cr |
| Fixed assetsFixed Assets | ₹28 Cr |
| Capital work in progressCWIP | ₹0 Cr |
| Investments | ₹277 Cr |
| Other assetsOther Assets | ₹1,498 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | -₹109 Cr |
| Investing cash flowCash from Investing Activity | ₹208 Cr |
| Financing cash flowCash from Financing Activity | -₹41 Cr |
| Change in cashNet Cash Flow | ₹58 Cr |
Learn while you research
Academy chapters picked for Entero Healthcare Solutions Limited and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Valuation Multiples ExplainedThis stock trades at a P/E of 124.0, learn when high multiples are justified.6 min read
- 04 Growth Investing29% revenue growth is in the top tier, learn how to value growth.7 min read
- 05 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 06 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read